eVusheld Assessment reaL wORld effectiveness in Israel Clalit Health Services - VALOR C19 IL

Inclusion Criteria

• • Aged 12 years and older as of the date of receipt of EVUSHELD
• • No record of infection or SARS-CoV- hospitalization within last 90 days prior to the index date
• • Individuals who are moderate/severe immune compromised due to a medical condition or receipt of immunosuppressive medications or treatments and may mount an adequate immune response to COVID-19 vaccine:
• • Hypogammaglobinemia patients regularly treated with immunoglobulins
• • Patients treated with B-cell depleting therapy, including for example such anti-CD20 as rituximab, obinatuzumab, ofatumumab, veltuzumab, Y-ibritumomab tiuxetan or ocrelizumab, even without malignant disease, up to six months from treatment.
• • Patients that are treated with B-cell depleting therapy (i.e. anti CD20, rituximab, Y-ibritumomab tiuxetan, veltuzumab, ofatumumab, obinatuzumab, ocrelizumab), without a malignant disease
• • Bone marrow transplant (up to a year from the BMT) from outside donors, or with GVHD grades 3-4.
• • Bone marrow transplant (up to a 6 months after the BMT) from self
• • Patients after (CAR) T-cell therapy (chimeric antigen receptor T-cell therapy) up to 6 months from the treatment.
• • Lungs transplant recipients
• • Solid organ transplant recipients (who has any kind of transplant) or those who received ATG (anti thymocyte globulin) over the last 6 months
• • Patients with aggressive lymphoma.
• • Multiple Myeloma patients that have active disease, and on treatment at the time of study initiation.
• Individuals who meet the criterion below will be excluded:
• Per the current FDA EUA, individuals currently infected with SARS-CoV-2 are not eligible for EVUSHELD as PrEP. Therefore, in the main analysis, individuals who meet the following criteria will also be excluded.